Exzolt

Active Ingredient:: Fluralaner
Brand:: Exzolt
Origin:: European Union

Exzolt (Fluralaner)

Fluralaner, the active ingredient in Exzolt, is an isoxazoline ectoparasiticide presented as a chewable tablet for oral use. It provides systemic control of fleas and ticks in dogs, eliminating existing parasites and preventing new infestations. The product is formulated for convenient administration and is approved for use in the European Union.

GNH India supplies Exzolt as a licensed, GDP‑compliant international pharmaceutical supplier serving pharmacies, clinics, and veterinary hospitals worldwide, adhering to stringent quality standards and regulatory requirements through reliable logistics networks.

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Exzolt (fluralaner) is an isoxazoline ectoparasiticide used to manage external parasite infestations in dogs.

Flea infestation: eliminates adult fleas and interrupts the life cycle, providing rapid relief.
Tick infestation: kills attached ticks and prevents attachment of new ticks, reducing disease transmission risk.
Re‑infestation prevention: maintains continuous protection for up to 12 weeks, helping to keep dogs free from fleas and ticks.

How It Works

Fluralaner binds to GABA‑gated and glutamate‑gated chloride channels in the nervous system of arthropods. By blocking these inhibitory pathways, it causes uncontrolled neuronal firing, leading to hyperexcitation, paralysis, and death of fleas and ticks that ingest the drug systemically after oral administration.

Side Effects

Exzolt may be associated with a range of adverse reactions in treated animals.

Common Side Effects

Vomiting: mild to moderate gastrointestinal upset.
Diarrhea: loose stools that usually resolve spontaneously.
Decreased appetite: temporary reduction in food intake.
Lethargy: mild fatigue or reduced activity.
Skin irritation: localized redness at the site of chewing.
Salivation: increased drooling after administration.

Serious or Rare Side Effects

Seizures: neurological events requiring immediate veterinary attention.
Anaphylaxis: severe allergic reaction with swelling, hives, or respiratory distress.
Hepatic enzyme elevation: abnormal liver function tests.
Neutropenia: reduced white blood cell count.
Severe gastrointestinal ulceration: persistent vomiting or blood in stool.
Sudden death: extremely rare but reported in susceptible individuals.

Precautions & Warnings

When using Exzolt, follow veterinary guidance and observe the following precautions.

Species restriction: use only in dogs as directed by a veterinarian.
Age limitation: do not administer to puppies younger than eight weeks.
Weight consideration: ensure the dog meets the minimum weight requirement for the selected dose.
Health status: avoid use in animals with known hypersensitivity to isoxazolines.
Concomitant ectoparasiticides: do not combine with other flea or tick products without veterinary approval.
Pregnancy and lactation: consult a veterinarian before use in breeding or lactating dogs.
Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Avoid Interactions

Exzolt may interact with other medicines; monitor the following.

Major Interactions (Avoid)

Concurrent use with other isoxazoline ectoparasiticides: increased risk of neurotoxicity.
Strong CYP3A4 inhibitors (e.g., ketoconazole): may raise systemic fluralaner levels.
Drugs that lower seizure threshold: potential for heightened neurologic events.

Moderate Interactions (Monitor Closely)

Oral anti‑inflammatory drugs: may affect gastrointestinal tolerance.
Vaccines: schedule administration at least 24 hours apart to avoid overlapping adverse reactions.
Food intake: high‑fat meals can delay absorption, requiring observation of efficacy.

Frequently Asked Questions

Exzolt is a veterinary product containing fluralaner that provides systemic control of fleas and ticks on dogs. It eliminates existing parasites and offers ongoing protection to prevent new infestations for several weeks.

Fluralaner targets GABA‑gated and glutamate‑gated chloride channels in arthropod nerves. By blocking these inhibitory channels, it causes uncontrolled neuronal firing, leading to paralysis and death of fleas and ticks that feed on the treated animal.

The dose of Exzolt is determined by a veterinarian based on the dog’s weight, age, and health status. The prescriber selects the appropriate chewable tablet strength to achieve effective parasite control.

Safety data for use in pregnant or lactating dogs are limited. Veterinarians should evaluate the risk‑benefit ratio before prescribing Exzolt to breeding, pregnant, or nursing animals.

To request Exzolt, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Exzolt belongs to the isoxazoline class, which offers rapid kill and long‑lasting protection compared with older insecticide classes. It typically provides up to 12 weeks of efficacy, whereas many alternative products require monthly dosing.

Store Exzolt at ambient temperature, preferably below 25 °C. Keep the tablets in the original packaging, protect them from moisture and direct sunlight, and avoid storing near heat sources.

Exzolt is given orally as a chewable tablet. The tablet can be offered directly to the dog or hidden in food. Administration should follow the veterinarian’s instructions regarding timing and any required fasting.

Serious adverse events, although rare, include seizures, severe allergic reactions such as anaphylaxis, and significant hepatic or hematologic abnormalities. Owners should seek immediate veterinary care if any of these signs appear.

Exzolt should not be used in dogs younger than eight weeks, in animals with a known hypersensitivity to isoxazolines, or in dogs receiving other isoxazoline ectoparasiticides without veterinary approval.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 29 Jul 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Exzolt (Fluralaner)

Indications & Clinical Uses

How It Works